Tag: report

Company delivers record second quarter revenue, meets or exceeds all guidance metrics

Discover comprehensive insights with the "Hypocobalaminemia (Vitamin B12) Deficiency - Global Clinical Trials Review, 2025." This report covers the global landscape of Vitamin B12 deficiency trials, with detailed data by region, country, and phase. Optimize strategies with top-line analysis of trial trends and key opportunities.

A webinar on the presentation of the results (in Estonian only) will take place on 31 July at 13:00 (EEST), more information.

Sales Revenues and Profitability

(OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md., US, July 31, 2025) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announced that it will report second quarter financial results, before the US markets open on Thursday, August 7, 2025.

Company Announcement No. 1159

Q2 2025 RESULTS¹
Net income group share at EUR 271 million, up 38.5% vs. Q2 2024

CAMBRIDGE, Mass., July 30, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced the pricing of an underwritten public offering of 38,000,000 shares of its common stock at a public offering price of $3.30 per share. The underwriters will not receive any discounts or commissions with respect to an aggregate of 1,818,181 shares of common stock sold to the Cystic Fibrosis Foundation. Prime Medicine has also granted the underwriters a 30-day option to purchase up to an additional 5,700,000 shares of its common stock. The gross proceeds to Prime Medicine from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be approximately $125.4 million, excluding any exercise of the underwriters’ option to purchase additional shares. All of the shares of common stock in the offering are to be sold by Prime Medicine. The offering is expected to close on or about August 1, 2025, subject to satisfaction of customary closing conditions.